Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer—Immun-HER trial (GOIRC-01-2016)
Benedetta Pellegrino(University of Parma), Antonino Musolino(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Lorenzo Gianni, Olga Serra(University of Parma), Luisa Carbognin(Agostino Gemelli University Polyclinic), Elisabetta Cretella(Ospedale di Bolzano), Claudio Zamagni(Policlinico S.Orsola-Malpighi), Stefania Gori(Ospedale Sacro Cuore Don Calabria), Renata Todeschini(University of Parma), Filippo Montemurro(Roche (Switzerland)), Emilio Bria(Università Cattolica del Sacro Cuore), Alberto Zambelli, Giancarlo Bisagni, Michele Tognetto(University of Aberdeen), Chiara Tommasi(University of Parma), Antonella Mura(Azienda USL di Bologna), Nicoletta Campanini(University of Parma), Giuseppe Maglietta(University of Parma), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Gabriele Missale(University of Parma), Elena Fiorio(University of Verona), Enrico Maria Silini(Ospedale di Parma), Massimo Ambroggi(Guglielmo da Saliceto Hospital), Chiara Casarini(Azienda Unita' Sanitaria Locale Di Modena)
Cited by 10
Related Papers
An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors
|Proceedings of the National Academy of Sciences|2002|963
Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism
|Nature Medicine|2000|931
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response.
|Journal of Clinical Investigation|1996|661
Distance as a Barrier to Cancer Diagnosis and Treatment: Review of the Literature
|The Oncologist|2015|531